Bayer confirms 2025 targets after solid start to the year

 Group sales at 13.738 billion euros (Fx & p adj. minus 0.1 percent) / EBITDA before special items decreases to 4.085 billion euros (minus 7.4 percent) / Moderate decline in sales (Fx & p adj.) at Crop Science, earnings down year on year / Pharmaceuticals posts higher sales, earnings significantly above prior-year level / Sales and earnings up at Consumer Health / Core earnings per share at 2.49 euros (minus 11.7 percent) / Net income at 1.299 billion euros / Free cash flow improves to minus 1.528 billion euros / Net financial debt at 34.255 billion euros / Currency-adjusted Group outlook confirmed / Execution of five-year plan for Crop Science under way 

https://www.bayer.com/media/en-us/bayer-confirms-2025-targets-after-solid-start-to-the-year/